<code id='7B95F8C727'></code><style id='7B95F8C727'></style>
    • <acronym id='7B95F8C727'></acronym>
      <center id='7B95F8C727'><center id='7B95F8C727'><tfoot id='7B95F8C727'></tfoot></center><abbr id='7B95F8C727'><dir id='7B95F8C727'><tfoot id='7B95F8C727'></tfoot><noframes id='7B95F8C727'>

    • <optgroup id='7B95F8C727'><strike id='7B95F8C727'><sup id='7B95F8C727'></sup></strike><code id='7B95F8C727'></code></optgroup>
        1. <b id='7B95F8C727'><label id='7B95F8C727'><select id='7B95F8C727'><dt id='7B95F8C727'><span id='7B95F8C727'></span></dt></select></label></b><u id='7B95F8C727'></u>
          <i id='7B95F8C727'><strike id='7B95F8C727'><tt id='7B95F8C727'><pre id='7B95F8C727'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:leisure time    Page View:56
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In